On July 2, the FDA granted accelerated approval to sunvozertinib for adult patients with locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.

For more information, read the FDA announcement and visit the Dizal (Jiangsu) Pharmaceutical website.

Posted on 7/7/2025